European Journal of Clinical Pharmacology

European Journal of Clinical Pharmacology is published by Springer Berlin Heidelberg and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Antibiotics Pharmacokinetics and Efficacy and Analytical Methods in Pharmaceuticals, together about 25.2% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves a compound that is interesting and new in some basic or fundamental way, or methods that are original in some basic sense, or a highly unexpected outcome, or conclusions that are scientifically novel in some basic or fundamental sense. Straightforward descriptive data in drug utilization will only be considered if more than one geographical area is studied and if a scientific hypothesis is tested or an intervention carried out. Descriptive data in drug utilization can however be quite useful in a more local setting. Again, if conceptually new methods, analysis, or ways of reasoning are involved, this would elicit greater interest from the international scientific community. In such a case, we would welcome submission to the EJCP and evaluate the paper according to standard procedures. The Journal also accepts review articles on various topics related to drug action in man. Debate on controversial issues is also encouraged, usually in the form of a letter to the editor that comments on a paper published in the Journal. Case reports on new findings or a new understanding of a mechanism of action should usually also be submitted in the form of a letter to the editor.

From the journal's Aims & Scope

Research area (LetPub): Pharmacology & Pharmacy

Editorial board by country: 1 in mainland China (about 1%); most named Germany 19, Sweden 11, United Kingdom 8, Spain 6, Italy 5 (83 members with a country) Editorial board ↗Publisher website · 2026-09-29

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINEEmbaseCASCAB AbstractsCurrent ContentsPublisher website

Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, AGRICOLA, Naver, OCLC, Portico, CLOCKSS

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

3.49LetPub · 2026-09-13

Impact factor (publisher) 2025

3.5Publisher website · 2026-09-29

5-year impact factor (publisher) 2025

3Publisher website · 2026-09-29

CiteScore 2026-06

5.6LetPub · 2026-09-13

SJR 2026-06

0.89LetPub · 2026-09-13

SNIP 2026-06

1.15LetPub · 2026-09-13

h-index

99LetPub · 2026-09-13

h-index

163OpenAlex · 2026-10-01

i10-index

6,980OpenAlex · 2026-10-01

2-year mean citedness

3.1OpenAlex · 2026-10-01

Self-citation rate

2.9%LetPub · 2026-09-13

Share of gold OA articles

29.41%LetPub · 2026-09-13

Volume

Articles per year

126LetPub · 2026-09-13

Downloads per year (publisher) 2025

1,100,000Publisher website · 2026-09-29

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

3–8 weeksLetPub · 2026-09-13

Average acceptance (community reports)

EasyLetPub · 2026-09-13

Submission to first decision

7 daysPublisher website · 2026-09-29

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Springer Berlin Heidelberg

Country or region

GERMANY

Language

English

Frequency

Monthly

Founded

1968

ISSN

0031-6970

Electronic ISSN

1432-1041

Society / sponsor

European Association of Clinical Pharmacology & Therapeutics

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗LetPub
• Author guidelines ↗LetPub